We’ve recently updated our valuation analysis.

Alpha Teknova Valuation

Is TKNO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TKNO?

Other financial metrics that can be useful for relative valuation.

TKNO key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3.4x
Enterprise Value/EBITDA-7.1x
PEG Ration/a

Price to Sales Ratio vs Peers

How does TKNO's PS Ratio compare to its peers?

The above table shows the PS ratio for TKNO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average3.4x
BLI Berkeley Lights
1.9x17.7%US$159.8m
CDXC ChromaDex
2x19.4%US$136.6m
IPA ImmunoPrecise Antibodies
8.4x16.5%US$124.4m
LAB Standard BioTools
1.5xn/aUS$160.2m
TKNO Alpha Teknova
3.7x18.9%US$160.3m

Price-To-Sales vs Peers: TKNO is expensive based on its Price-To-Sales Ratio (3.7x) compared to the peer average (3.4x).


Price to Earnings Ratio vs Industry

How does TKNO's PE Ratio compare vs other companies in the US Life Sciences Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a14.6%
n/an/an/a

Price-To-Sales vs Industry: TKNO is good value based on its Price-To-Sales Ratio (3.7x) compared to the US Life Sciences industry average (4.9x)


Price to Sales Ratio vs Fair Ratio

What is TKNO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TKNO PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.7x
Fair PS Ratio3.5x

Price-To-Sales vs Fair Ratio: TKNO is expensive based on its Price-To-Sales Ratio (3.7x) compared to the estimated Fair Price-To-Sales Ratio (3.5x).


Share Price vs Fair Value

What is the Fair Price of TKNO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate TKNO's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate TKNO's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst TKNO forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$5.70
US$9.00
+57.9%
11.1%US$10.00US$8.00n/a2
Jan ’24US$5.64
US$10.00
+77.3%
20.0%US$12.00US$8.00n/a2
Dec ’23US$4.85
US$10.00
+106.2%
20.0%US$12.00US$8.00n/a2
Nov ’23US$4.74
US$13.50
+184.8%
3.7%US$14.00US$13.00n/a2
Oct ’23US$3.34
US$14.00
+319.2%
7.1%US$15.00US$13.00n/a2
Sep ’23US$4.42
US$14.00
+216.7%
7.1%US$15.00US$13.00n/a2
Aug ’23US$6.75
US$21.00
+211.1%
4.8%US$22.00US$20.00n/a2
Jul ’23US$8.16
US$23.00
+181.9%
13.0%US$26.00US$20.00n/a2
Jun ’23US$7.75
US$23.00
+196.8%
13.0%US$26.00US$20.00n/a2
May ’23US$11.23
US$28.00
+149.3%
5.8%US$30.00US$26.00n/a3
Apr ’23US$14.46
US$28.00
+93.6%
5.8%US$30.00US$26.00n/a3
Mar ’23US$17.02
US$29.00
+70.4%
3.4%US$30.00US$28.00n/a2
Feb ’23US$15.78
US$29.33
+85.9%
3.2%US$30.00US$28.00n/a3
Jan ’23US$20.48
US$29.33
+43.2%
3.2%US$30.00US$28.00US$5.643
Dec ’22US$20.30
US$29.33
+44.5%
3.2%US$30.00US$28.00US$4.853
Nov ’22US$23.00
US$27.67
+20.3%
6.1%US$30.00US$26.00US$4.743
Oct ’22US$26.72
US$25.67
-3.9%
4.9%US$27.00US$24.00US$3.343
Sep ’22US$18.56
US$25.67
+38.3%
4.9%US$27.00US$24.00US$4.423
Aug ’22US$22.22
US$25.67
+15.5%
4.9%US$27.00US$24.00US$6.753

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies